Inovio Pharmaceuticals has concluded patient recruitment in Pennvax-B DNA vaccine Phase I clinical study, delivered using its proprietary electroporation technology in a preventive setting.
The multi-center study is being conducted by Inovio’s clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.
Inovio previously reported data from non-human primates demonstrating up to a 100-fold enhancement in immune responses resulting from the vaccine when delivered via in-vivo electroporation compared to syringe injection without electroporation.
Vanderbilt University Medical Center, Vanderbilt Center for AIDS Research immunology director Spyros Kalams said that enrollment for this trial was completed ahead of schedule, with much anticipation for assessing this new concept for HIV vaccines.
“We look forward to the results of this DNA vaccine trial with its unique mode of action and novel delivery technology,” Kalams said.